Brigatinib/Brigatinib (Embry) belongs to the first generation of targeted therapy drugs

Brigatinib/Brigatinib (Brigatinib) is an oral small molecule tyrosine kinase inhibitor (TKI), mainly targeting ALK-positive non-small cell lung cancer (NSCLC). Judging from the history of drug development, it is classified as a second-generation ALK targeted therapy drug. After the advent of the first-generation ALK inhibitor crizotinib, although patients' treatment prospects have significantly improved, drug resistance and insufficient control of brain metastases have gradually become clinical problems. Therefore, researchers are committed to developing more efficient molecules, and it is in this context that brigatinib emerged.

Compared with the first-generation drugs, brigatinib not only has a stronger inhibitory effect onALK fusion gene, but also exhibits activity against multiple mutation sites, which allows it to continue to work after patients develop resistance to crizotinib. Especially in terms of controlling brain metastasis, brigatinib has strong blood-brain barrier penetration ability, providing a more reliable option for patients carrying ALK-positive mutations and accompanied by central nervous system metastasis. This advantage makes it regarded as one of the representative second-generation ALK-TKI drugs in clinical practice.

From the perspective of international application, brigatinib has been approved by the USFDA and the European Food and Drug Administration and is suitable for patients who have failed crizotinib treatment. Subsequently, its marketing was successively approved in China, allowing Chinese patients with ALK-positive lung cancer to simultaneously benefit from this advanced drug. Compared with other second-generation ALK inhibitors (such as ceritinib and alectinib), brigatinib has differentiated advantages in speed of onset of action and broad-spectrum mutation suppression, and therefore has been gradually included in more guidelines and clinical pathways.

The generational development of targeted drugs not only reflects the upgrade of molecular structures, but also reflects the deepening of the concept of precision medicine. As a second-generation ALK inhibitor, brigatinib is continuously consolidating its position in the treatment of ALK-positive non-small cell lung cancer.

Reference materials:https://www.alunbrig.com/